Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
2'-5'-Oligoadenylate synthetase 3 (OAS3) is an interferon-stimulated enzyme central to innate antiviral immunity. It contains three tandem OAS domains but only the third (C-terminal) domain is catalytically active. Upon binding long double-stranded RNA (dsRNA), as produced during viral infection, OAS3 synthesizes 2’-5’ linked oligoadenylates (2-5As) from ATP. These 2-5As function as second messengers, activating the latent endoribonuclease RNase L. Activated RNase L degrades viral and cellular RNA, inhibiting viral replication and triggering apoptotic or stress pathways in infected cells. OAS3 is more sensitive to dsRNA than other OAS family members and preferentially produces oligoadenylates of sufficient length to robustly activate RNase L. OAS3 thus serves as both a sensor of cytosolic dsRNA and as a regulator of downstream antiviral responses, playing a critical role in interferon-induced cellular defenses[1][2][3].
Induction of 2'-5'-oligoadenylate synthesis upon dsRNA binding, leading to RNase L pathway activation and cellular/viral RNA degradation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 2'-5'-oligoadenylate synthetase 3 (OAS3).